Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1‐like response

The Leishmania major amastigote class I nuclease (LmaCIN) is a developmentally regulated protein that is highly expressed in the amastigote stage of L. major. This protein is homologous to the P4 nuclease of L. pifanoi, which has been shown to induce protective immune response in a murine model. To evaluate LmaCIN as a potential human vaccine candidate, cellular immune responses to recombinant LmaCIN were examined in individuals recovered from Old World cutaneous leishmaniasis. Peripheral blood mononuclear cells (PBMC) from patients recovered from L. major infection were cultured either with recombinant LmaCIN or autoclaved L. major (ALM) as control. rLmaCIN induced significant proliferation of PBMC from 90% of recovered patients. Phenotypic analysis of proliferating cells showed that CD8+ cells were the predominant cell type proliferating in response to rLmaC1N. Screening of culture supernatants for cytokines showed that rLmaCIN induced high levels of interferon (IFN)‐γ (mean ± s.e.m.: 1398 ± 179 pg/ml) associated with little interleukin (IL)‐10 and little or no IL‐5 production. These findings show that LmaCIN is immunogenic in humans during L. major infection and that it can elicit immunological responses relevant to immunoprophylaxis of leishmaniasis.

[1]  N. Reiner,et al.  Molecular characterization of a novel amastigote stage specific Class I nuclease from Leishmania major. , 2004, International journal for parasitology.

[2]  K. Campbell,et al.  DNA Immunization with the Gene Encoding P4 Nuclease of Leishmania amazonensis Protects Mice against Cutaneous Leishmaniasis , 2003, Infection and Immunity.

[3]  S. Croft,et al.  Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs. , 2003, Trends in parasitology.

[4]  D. Mcmahon-Pratt,et al.  Perforin and Gamma Interferon Are Critical CD8+ T-Cell-Mediated Responses in Vaccine-Induced Immunity against Leishmania amazonensis Infection , 2003, Infection and Immunity.

[5]  D. Mcmahon-Pratt,et al.  Evaluation of amastigote reactive cells in human cutaneous leishmaniasis caused by Leishmania aethiopica , 2003, Clinical and experimental immunology.

[6]  A. Khamesipour,et al.  The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. , 2002, Vaccine.

[7]  C. Auriault,et al.  IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection. , 2002, Parasitology international.

[8]  D. Sacks,et al.  The immunology of susceptibility and resistance to Leishmania major in mice , 2002, Nature Reviews Immunology.

[9]  Y. Belkaid,et al.  CD8+ T Cells Are Required for Primary Immunity in C57BL/6 Mice Following Low-Dose, Intradermal Challenge with Leishmania major , 2002, The Journal of Immunology.

[10]  A. Debrabant,et al.  Developmentally regulated expression of a cell surface class I nuclease in Leishmania mexicana. , 2002, International journal for parasitology.

[11]  S. Coutinho,et al.  T-Cell-Mediated Immune Responses in Patients with Cutaneous or Mucosal Leishmaniasis: Long-Term Evaluation after Therapy , 2002, Clinical and Vaccine Immunology.

[12]  Y. Belkaid,et al.  The Role of Interleukin (IL)-10 in the Persistence of Leishmania major in the Skin after Healing and the Therapeutic Potential of Anti–IL-10 Receptor Antibody for Sterile Cure , 2001, The Journal of experimental medicine.

[13]  D. Wolday,et al.  Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis , 2001, Clinical and experimental immunology.

[14]  Y. Belkaid,et al.  The Potency and Durability of DNA- and Protein-Based Vaccines Against Leishmania major Evaluated Using Low-Dose, Intradermal Challenge , 2001, The Journal of Immunology.

[15]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[16]  S. Kar,et al.  The immunologically protective P-4 antigen of Leishmania amastigotes. A developmentally regulated single strand-specific nuclease associated with the endoplasmic reticulum. , 2000, The Journal of biological chemistry.

[17]  S. Jeronimo,et al.  IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. , 2000, Cytokine.

[18]  F. Koning,et al.  A Leishmania homologue of receptors for activated C-kinase (LACK) induces both interferon-gamma and interleukin-10 in natural killer cells of healthy blood donors. , 2000, The Journal of infectious diseases.

[19]  John T. Chang,et al.  Requirements for the Maintenance of Th1 Immunity In Vivo Following DNA Vaccination: A Potential Immunoregulatory Role for CD8+ T Cells , 2000, The Journal of Immunology.

[20]  E. Ghedin,et al.  Dissection of the Functional Domains of theLeishmania Surface Membrane 3′-Nucleotidase/Nuclease, a Unique Member of the Class I Nuclease Family* , 2000, The Journal of Biological Chemistry.

[21]  R. Coffman,et al.  Experimental Leishmania major infection in mice: role of IL‐10 , 1999, Parasite immunology.

[22]  S. Gurunathan,et al.  Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection , 1998, Nature Medicine.

[23]  S. Reed,et al.  Human and Murine Immune Responses to a NovelLeishmania major Recombinant Protein Encoded by Members of a Multicopy Gene Family , 1998, Infection and Immunity.

[24]  D. Mcmahon-Pratt,et al.  Leishmania pifanoi Amastigote Antigen P-4: Epitopes Involved in T-Cell Responsiveness in Human Cutaneous Leishmaniasis , 1998, Infection and Immunity.

[25]  S. Reed,et al.  Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. , 1996, Journal of immunology.

[26]  D. Mcmahon-Pratt,et al.  T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. , 1996, Experimental parasitology.

[27]  J. Streit,et al.  Visceral Leishmaniasis , 2011 .

[28]  A. Satoskar,et al.  Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection , 1995, Infection and immunity.

[29]  T. Baldwin,et al.  Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response , 1995, Infection and immunity.

[30]  D. Mcmahon-Pratt,et al.  Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun 63 , 1995 .

[31]  A. Debrabant,et al.  Isolation and characterization of the gene encoding the surface membrane 3'-nucleotidase/nuclease of Leishmania donovani. , 1995, Molecular and biochemical parasitology.

[32]  G. Trinchieri,et al.  A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12 , 1995, The Journal of experimental medicine.

[33]  P. Romero,et al.  Leishmania major infection in mice primes for specific major histocompatibility complex class I‐restricted CD8+ cytotoxic T cell responses , 1994, European journal of immunology.

[34]  J. Louis,et al.  Expansion of gamma interferon-producing CD8+ T cells following secondary infection of mice immune to Leishmania major , 1994, Infection and immunity.

[35]  T. Theander,et al.  Dichotomy of the human T cell response to Leishmania antigens. I. Th1‐like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis , 1994, Clinical and experimental immunology.

[36]  H. Akuffo,et al.  Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through the stimulation of natural killer (NK) cells , 1993, Clinical and experimental immunology.

[37]  R. Pearson,et al.  Potential role for interleukin-10 in the immunosuppression associated with kala azar. , 1993, The Journal of clinical investigation.

[38]  A. Kharazmi,et al.  Evaluation of the efficacy of Iran leishmanin and comparison with leishmanins from Wellcome (UK) and Roma (Italy) in cured cutaneous leishmaniasis patients. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[39]  J. Louis,et al.  Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells , 1993, Infection and immunity.

[40]  P. Scott,et al.  Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis , 1993, Infection and immunity.

[41]  Mohamed,et al.  Interleukin 10 production correlates with pathology in human Leishmania donovani infections. , 1993, The Journal of clinical investigation.

[42]  G. O. Gbenle,et al.  Purification and properties of 3'-nucleotidase of Leishmania donovani. , 1992, The Biochemical journal.

[43]  P. Melby.  Experimental leishmaniasis in humans: review. , 1991, Reviews of infectious diseases.

[44]  J. Sacci,et al.  Purification and characterization of the 3'-nucleotidase/nuclease from promastigotes of Leishmania donovani. , 1991, Molecular and biochemical parasitology.

[45]  R. Locksley,et al.  Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. , 1991, Immunology today.

[46]  T. Neubert,et al.  An inducible 3'-nucleotidase/nuclease from the trypanosomatid Crithidia luciliae. Purification and characterization. , 1990, The Journal of biological chemistry.

[47]  E. Handman,et al.  Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice. , 1990, Experimental parasitology.

[48]  L. Schnur,et al.  Delayed-type hypersensitivity and lymphocyte proliferation in response to Leishmania major infection in a group of children in Jericho. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[49]  D. Mcmahon-Pratt,et al.  Membrane glycoprotein M-2 protects against Leishmania amazonensis infection , 1988, Infection and immunity.

[50]  A. Goldstein,et al.  Purification and properties , 1975 .

[51]  D. Heyneman.  Immunology of leishmaniasis. , 1971, Bulletin of the World Health Organization.